首页> 外文期刊>Perspectives in Clinical Research >Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
【24h】

Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites

机译:在印度开展乳腺癌和肺癌临床试验的可行性研究

获取原文
           

摘要

Objective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 patients per month, frequency of Ethics Committee (EC) meeting ≤4 weeks, dropout rate Results: For both indications, 50/300 (16.7%) sites responded. The median number of patients seen by a site per month for breast and lung cancer was 20 (range 0-300) and 10 (range 0-75), respectively. Median number of eligible patients was 4 (range 0-20) and 3 (range 0-15) per month, for breast and lung cancer respectively. The frequency of EC meeting was ≤4 weeks at 36-56% of sites. All sites were trained in GCP and had adequate infrastructure to conduct the clinical trial. For breast cancer 22 (44%) sites (public 14 [28%]; private 8 [16%)]), and for lung cancer 18 (36%) sites (public 15 [30%], private: 3 [6%]) met the criteria of selection. Conclusion: Preliminary feasibility study would require for confirmation of the important feasibility criteria by in depth discussion during the personal visit to the potential sites.
机译:目的:本研究的目的是在印度进行III期乳腺癌和肺癌临床试验的可行性研究。材料和方法:将研究概要和可行性调查表邮寄给300名肿瘤科医生,以适应各种适应症。选择标准为每月入院≥2名患者,伦理委员会(EC)开会频率≤4周,辍学率结果:对于这两种适应症,有50/300(16.7%)个部位有反应。每月每个站点看到的乳腺癌和肺癌患者的中位数分别为20(范围为0-300)和10(范围为0-75)。乳腺癌和肺癌的合格患者中位数分别为每月4名(范围0-20)和3名(范围0-15)。在36-56%的地点,EC会议的频率≤4周。所有站点都接受了GCP培训,并拥有足够的基础设施来进行临床试验。对于乳腺癌22(44%)个部位(公共14 [28%];私人8 [16%]])和对于肺癌18(36%)个部位(公共15 [30%],私人:3 [6% ])符合选择标准。结论:初步的可行性研究将需要通过在潜在站点的个人访问期间进行深入讨论来确认重要的可行性标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号